and dectin 1 is now known to induce the activation of calcineurin/NFAT signaling in myeloid cells, a finding which has provided new insights into the molecular pathways that regulate host protection.
Inhibitors of calcineurin/NFAT binding, such as cyclosporine A and FK506 are broadly used in organ transplantation and can act as potent immunosuppressive drugs in a variety of different disorders. There is increasing evidence that these agents influence innate responses as well as inhibiting adaptive T cell functions. This review focuses on the role of calcineurin/NFAT signaling in myeloid cells, which may contribute to the various unexplained effects of immunosuppressive drugs already being used in the clinic.
Introduction
Ligation of pattern recognition receptors (PRRs) results in the activation of the calcineurin/nuclear factor of activated T cells (NFAT) pathway in myeloid cells, as was first revealed by our discovery that dendritic cells (DCs) produce interleukin (IL)-2 after encountering microbial products.
1,2
NFAT-regulated genes have subsequently been shown to modulate the functions of a broad range of myeloid cells, including macrophages, mast cells, megakaryocytes and osteoclasts. In mice, NFAT signaling has now been shown to drive neutrophil-mediated resistance to Candida albicans 3 , and IL-2 production by DCs challenged with bacteria has been demonstrated both in vitro and in vivo, resulting in the activation of natural killer (NK) cells 4, 5 and regulatory T cells (Tregs). 6,7 NFATdependent genes also modulate DC life cycle in response to LPS activation, leading to the apoptosis of terminally differentiated DCs. 8 In addition, NFAT signaling has been shown to negatively regulate myeloid cell development 9 . Accordingly, NFAT expression levels are down regulated during myeloid differentiation of hematopoietic CD34 + stem cells (HSCs) . 10 These data indicate that, in addition to better-known roles for NFAT in lymphoid development, 11 the calcineurin/NFAT pathway plays a critical role in the development and function of innate myeloid cells.
Calcineurin/NFAT inhibitors such as cyclosporine A (CsA) and tacrolimus (FK506) are primarily used to prevent allograft rejection and to treat graft versus host disease (GVHD) after bone marrow transplantation. However, these drugs are also used to treat a wide variety of immune disorders that include atopic dermatitis and refractory colitis. Both CsA and FK506 are still broadly used to block the calcineurin/NFAT pathway although some effects in the modulation of other pathways have been reported. The newly discovered roles played by NFAT in the function of innate immune cells may contribute to the higher rates of infection observed in patients who receive calcineurin inhibitors or other immunosuppressive drugs. This review summarizes our current knowledge of NFAT functions in innate myeloid cells, with a particular focus on NFAT signaling in immune homeostasis and in the early phase of the innate response.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Calcineurin/NFAT signaling NFAT comprises a family of transcription factors that includes five members, four of which are regulated by Ca 2+ signaling; NFAT1 (NFATc2 or NFATp), NFAT2 (NFATc or NFATc1), NFAT3 (NFATc4), NFAT4 (NFATx or NFATc3) and calcineurin-independent NFAT5 (TonE-BP or NFATL1). Calcineurin is a key phosphatase that facilitates the translocation of NFAT molecules from the cytoplasm into the nucleus to regulate diverse cellular functions including proliferation, differentiation and development. NFAT was first identified more than 20 years ago as an inducible transcription factor that could bind to the IL-2 promoter to activate cytokine production following T cell activation 12 . The NFAT pathway has since been studied extensively in lymphocytes, but a key role for this signaling pathway in myeloid cells has now also been identified. 3, 8, 9 The classical calcineurin/NFAT signaling pathway in lymphocytes has been reviewed in detail elsewhere. 11, 13 In brief: upon antigen engagement of lymphocyte receptors, phospholipase C-γ (PLC-γ) becomes activated and hydrolyzes phosphatidylinositol-4, 5-bisphosphate (PIP 2 ) into inositol-1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG). IP 3 then binds to specific receptors on the endoplasmic reticulum (ER) and drives Ca 2+ release from the ER into the cytoplasm, which triggers STIM1 and Orai1-mediated opening of Ca 2+ release-activated Ca 2+ channels. As a result of increased intracellular Ca 2+ , the calcineurin enzyme becomes active and dephosphorylates NFAT, allowing NFAT translocation into the nucleus and subsequent regulation of gene expression. It should be noted however that NFAT must ultimately bind to additional transcription factors such as AP1 in order to regulate gene expression. In DCs, LPS engagement of toll-like receptor 4 (TLR4) and CD14 activates Src-family kinase and PLC-γ2 to drive the production of IP 3 and DAG 8, 14 ( Fig.1) . Interestingly, smooth LPS (sLPS) mediated activation of DCs is fully dependent on an extracellular source of Ca 2+ 8,14 , and hence the authors speculate that DCs, unlike lymphocytes, may not use Ca 2+ derived from the ER to support activation (Fig.1) . A similar mechanism for cell activation has also been suggested in B cells 16 .
A key function of NFAT in immune cells is to regulate the expression of potent immunomodulatory cytokines. In T cells, the downstream targets of NFAT include IL-2 growth factor which regulates lymphocyte development and activation, and may contribute to the overall function of Tregs by regulating their expansion, differentiation and survival. 7,17 NFAT1 also regulates the transcription of the polarizing cytokines interferon (IFN)-γ and IL-4 which drive T h 1/T h 2 cell differentiation. 18, 19 The distal cis-regulatory element of IL-10 cytokine is also bound by NFAT1 and IRF4 in activated Th1 and Th2 cells. 20 Similarly, IL-10 expression can be activated through a Ca 2+ signaling pathway in B cells upon B cell receptor stimulation. 21 Production of the Th1 cytokine subunit IL-12p40 has been shown to be induced by the cooperation of NFAT with ICSBP in RAW-264.7 cells activated with LPS and IFN-γ. 22 NFAT has also been reported to regulate several key modulators of innate immune responses, including the production of IL-3, which is required for T cell and myeloid lineage differentiation. 23 Furthermore, tumor necrosis factor alpha (TNF-α) in T cells is directly regulated by NFAT1 and NFAT2 through promoter occupation. 24 Indeed GM-CSF plays an essential role in myeloid cell development and is a direct transcriptional target of NFAT. 25 Other downstream targets of NFAT in innate immune cells 26 include early growth response 2 and 3 (Egr2, Egr3), and cyclooxygenase-2 (Cox2), which are involved in angiogenesis and inflammation.
NFAT phosphorylation state and export from the nucleus are critically regulated by several enzymes including casein kinase (CK1), glycogen synthase kinase 3 (GSK3), P38 and JUN N terminal kinase (JNK), as has been reviewed elsewhere. 17 A non-coding RNA NRON scaffold complex was recently reported to suppress NFAT translocation into the nucleus. 27, 28 The NRON scaffold is composed of a long intergenic non-coding RNA (lincRNA), a scaffold protein, an IQ motif containing GTPase activating protein (IQGAP), and three NFAT kinases (CK1, GSK3, and complex. This complex regulates nuclear translocation of the NF-kB subunit p65 and the activation of the canonical NF-kB pathway. It has also been shown that dectin 1 and TLR2 can cross-regulate in a Syk-independent manner, suggesting that dectin 1 may also modulate TLR signaling. There is also evidence that dectin 1 signaling leads to the activation of the non-canonical NF-kB pathway through Raf-1, which seems to be involved in cross-talk between TLR2 and dectin 1. 46 Interestingly, both TLR2/MyD88 and dectin 1/Syk signaling synergize for optimal production of IL-2 by DCs. Macrophages are a population of professional phagocytes that express NFAT1, 2, 4 3 a n d 5 6 0 ( induced by these drugs is mainly achieved by inhibition of T cell responses and has proven invaluable in reducing the risk of rejection after solid organ transplantation. Although widely accepted that the immunosuppression induced by calcineurin inhibitors is due to the blockade of NFAT translocation, which inhibits T cell cytokine production and limits the release of IL-2, the effects of CsA have now also been studied in detail in myeloid cells. These studies aimed to explain the increased rates of infection observed after administration of NFAT inhibitors in organtransplanted patients. In particular, treated allograft recipients frequently undergo fungal and viral infections, which increase the risk of transplant rejection. 97 Intriguingly, treatment with CsA can increase susceptibility to C. albicans infection in mice that lack conventional lymphocytes, 3
suggesting that the drug must also act on non-lymphoid cell types. These studies further showed that NFAT inhibition results in reduced production of anti-inflammatory cytokines including IL-10, which is critical for the resolution of inflammation after fungal infection. 98 Taken Taken as whole, these data indicate that myeloid cell inflammatory responses can be profoundly modulated by drugs that inhibit NFAT signaling, and thus have significant implications effects may have an immediate impact on innate responsiveness since GM-CSF drives the development of DCs and granulocytes as well as regulating the release of neutrophils from the bone marrow. 104 We recently identified NFAT as a negative regulator of myeloid development by using the VIVIT peptide to inhibit NFAT signaling in HSCs that were then used to reconstitute an irradiated host 9
. Compared with their control counterparts, the myeloid cells that developed from NFAT-impaired progenitors displayed an advantage in re-populating the myeloid compartment ( Fig.   3 ). These data also indicate that NFAT signaling participates in the negative regulation of the myeloid compartment by modulating genes that influence cell cycle progression and apoptosis. Accordingly, proliferation and differentiation of skin stem cells is enhanced by exposure to CsA, since their cell cycle is negatively regulated by NFAT.
107
Further studies have to address the roles of NFAT considering its complexity in expression and function. Thus, the newly described role of NFAT during myeloid cell development together with the overall positive or negative effects of NFAT signaling among differentiated cells has to be considered. While affecting hematopoiesis as well as both innate and adaptive immune responses, calcineurin/NFAT inhibitors might contribute to the outcome of treatment including higher susceptibility to infections.
Summary
Recent findings have confirmed that the role of NFAT signaling in the regulation of immune responses is broader than that originally described only in conventional T cells. NFAT is now known to contribute to hematopoiesis as well as innate and adaptive immune functions in a variety of myeloid lineage cells. Increasing evidence also points to a key role for the calcineurin/NFAT pathway in innate immune homeostasis.
These findings have improved our understanding of the molecular mechanisms that underpin various side effects of NFAT inhibitors that are used in the clinic, including perturbation of immune homeostasis and increased susceptibility to infections and malignancies. Recent data 1 7 from our laboratory have clearly indicated that NFAT negatively regulates myeloid differentiation and that inhibition of calcineurin/NFAT signaling enhances the development of myeloid cells. 9 It is therefore likely that effects on T cell responses cannot entirely explain increased susceptibility to infection in patients treated with drugs that inhibit calcineurin/NFAT binding. The NFAT pathway is remarkably active in the majority of innate cells following PRR activation. When exposed to microbes, innate cells deficient in NFAT signaling exhibit a radically different transcriptional profile and phenotype, which significantly alters the outcome of adaptive immunity (Fig.3) . It is possible that these effects also contribute to the higher susceptibility to fungal and viral infections observed in CsA/tacrolimus immunosuppressed patients.
NFAT signaling in innate immune cells must now be considered as a major influence on the efficacy of various therapies that are already being used in the clinic. It was recently shown that low-dose IL-2 was able to prevent GVHD in patients that received HSC transplants 108 . The low levels of IL-2 injected subcutaneously were sufficient to ameliorate symptoms of GVHD and were associated with the expansion of FoxP3 + Tregs. These data are consistent with the observation that GVHD prophylaxis with sirolimus, which inhibits T cell functions in a calcineurin-independent manner, is more effective than calcineurin inhibition in reducing risk of GVHD. 108 Furthermore, the local delivery of IL-2 was found to reduce the formation of atherosclerotic plaques in mice. 109 Thus activation of the transcription factor NFAT in myeloid cells leads to the profound modulation of innate immunity as well as influencing adaptive immune responses.
The outcome of NFAT signaling in myeloid cells can vary depending on the cell type and experimental conditions. Whether NFAT transcriptional activity is activating or inhibitory depends heavily on co-factors such as AP1 (Fos/Jun), MEF2, and GATA. Hence the balance of these cofactors present may determine the different outcomes observed in different cell types. In conclusion, it would seem that NFAT activation in DCs provides signals which diminish immune responses.
Apart from regulation of immune functions in DCs, the cell cycle and survival of both macrophages and NK cells is strongly influenced by NFAT, which may further alter the outcome of innate Conflict-of-interest disclosure: The authors declare no financial or commercial conflict of interests.
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